Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Quest Diagnostics Says Its Zika Virus Test Gets U.S. Approval

By Reuters Staff | on June 10, 2016 | 0 Comment
Uncategorized
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Quest Diagnostics Inc. says it has received emergency authorization from the U.S. Food and Drug Administration (FDA) to sell the first commercially developed diagnostic test for Zika in the United States, a step that may help expand testing capacity and speed diagnosis of the virus.

You Might Also Like
  • More U.S. Babies with Zika-Related Birth Defects Reported by Health Agency
  • FDA Recommends Zika Testing for All Blood Donated in U.S.
  • Zika Infections in Puerto Rico Increasing Steadily

Previously, the only Zika blood tests that had Emergency Use Authorization, or EUA, were available from the U.S. Centers for Disease Control and Prevention (CDC) and were only to be used in qualified laboratories designated by the CDC.

Quest, in its announcement on Thursday (4/28/16), said it plans to make the new test broadly available to doctors for patient testing, including in Puerto Rico, by early next week.

Currently, the only laboratory that will use the new Zika test is at Quest’s reference laboratory in San Juan Capistrano, California, where the test was developed and validated. But the Emergency Use Authorization may allow for testing at other qualified laboratories, including one in Puerto Rico, Quest said in a statement.

Quest’s molecular test for Zika can only detect the virus when it is still present in the blood. A negative test does not completely rule out Zika infection. Further serological tests that look for antibodies made in response to the virus can help confirm infection. Quest said it is exploring options to make serological tests for Zika available as well.

The FDA’s authorization is for emergency use, and does not constitute FDA approval. The World Health Organization (WHO) declared the Zika outbreak an international health emergency on Feb. 1. The outbreak is affecting large parts of Latin America and the Caribbean, with Brazil the hardest hit so far.

U.S. health officials have concluded that Zika infections in pregnant women can cause microcephaly, a birth defect marked by small head size that can lead to severe developmental problems in babies.

The WHO has said there is strong scientific consensus that Zika can also cause Guillain-Barre, a rare neurological syndrome that causes temporary paralysis in adults. The connection between Zika and microcephaly first came to light last fall in Brazil, which has now confirmed more than 1,100 cases of microcephaly that it considers to be related to Zika infections in the mothers.

Topics: Diagnostic TestFDAGuillain-Barré SyndromeInfectious DiseaseLab TestMicrocephalyPregnancyQuest DiagnosticsZika Virus

Related

  • New Recommendations for Administering RhD IG at Less than 12 Weeks

    May 7, 2025 - 0 Comment
  • How to Diagnose and Manage Hypertensive Disorders in Pregnancy

    March 10, 2025 - 0 Comment
  • Peripartum Cardiovascular Disease Is Rare, But Serious

    December 31, 2024 - 0 Comment

Current Issue

ACEP Now: July 2025

Download PDF

Read More

No Responses to “Quest Diagnostics Says Its Zika Virus Test Gets U.S. Approval”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Current Issue

ACEP Now: July 2025

Download PDF

Read More

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603